Lineage Cell Therapeutics, Inc.

98 articles with Lineage Cell Therapeutics, Inc.

• RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

  3/20/2023

  Lineage Cell Therapeutics, Inc. today announced that results from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute.

• Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/9/2023

  Lineage Cell Therapeutics, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2022 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.

• RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

  3/6/2023

  Lineage Cell Therapeutics, Inc. today announced that results from imaging analyses of structural changes in addition to visual data from a Phase 1/2a clinical study of RG6501.

• Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

  3/2/2023

  Lineage Cell Therapeutics, Inc. today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets.

• Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

  2/22/2023

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc. (“Eterna”) for the development of novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into differentiated cell transplant therapies.

• Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

  2/22/2023

  Eterna Therapeutics Inc. today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Lineage Cell Therapeutics, Inc.  (“Lineage”) for the development of novel induced hypoimmune pluripotent stem cell (iPSC),

• Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

  2/8/2023

  Lineage Cell Therapeutics, Inc. today provided an update on its auditory neuronal cell therapy program (ANP1), for the treatment of hearing loss, with an initial focus on auditory neuropathy spectrum disorders.

• Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

  11/29/2022

  Fireside Chat with BTIG Research Scheduled for November 29, 2022 at 12:00pm Eastern.

• Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  11/28/2022

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that its partner Genentech, a member of the Roche Group, has launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 (OpRegen), a retinal pigment epithelial cell therapy.

• Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter of 2022.

• 

  Movers & Shakers: Ambrx, ADC Therapeutics, ImmunoGen and More get New C-Suites

  11/4/2022

  The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.

• Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022

  11/3/2022

  Lineage Cell Therapeutics, Inc. today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 10, 2022, following the close of the U.S. financial markets.

• Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

  10/31/2022

  Lineage Cell Therapeutics, Inc. announced today that Jill Howe will join as the Company’s Chief Financial Officer, effective November 14, 2022.

• Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

  10/10/2022

  Lineage Cell Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to grant a patent for the Company’s U.S. patent application No. 16/750,975, entitled “Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells.”

• Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa

  10/4/2022

  Lineage Cell Therapeutics, Inc. announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa , on October 12th , 2022 at 2:15pm PT / 5:15pm ET at the Park Hyatt Aviara, Carlsbad, CA.

• Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel

  10/3/2022

  Lineage Cell Therapeutics, Inc. announced the opening of a new research and development facility in Carlsbad, California, and the expansion of its Good Manufacturing Practice manufacturing facility based in Jerusalem, Israel.

• Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference

  8/15/2022

  Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference.

• Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/11/2022

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter of 2022.

• Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

  8/4/2022

  Lineage Cell Therapeutics, Inc. today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 2022, following the close of the U.S. financial markets.

• Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology

  6/2/2022

  Lineage Broadens Collaboration With Advanced BioMatrix for HyStem ® Cell Drug Delivery Technology.